Javiera Canales Abarca

Innovation in cellular therapy, antibody-drug conjugates (ADCs), and precision oncology set the tone for Day 1 of the 2026 ASCO Breakthrough Annual Meeting, where global experts highlighted how rapidly cancer treatment continues to evolve across both solid tumors and hematologic malignancies.

CAR T-cell therapy has proven to be a widely adopted treatment across many disease states in oncology, and lymphoma is among one of the most prevalent. At the same time, many unique challenges emerge that providers may be more unfamiliar with compared with some of its alternatives.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of an indication extension for teclistamab-cqyv (Tecvayli) in combination with daratumumab (Darzalex) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior therapy, according to a news release from Johnson & Johnson.1 The recommendation is supported by data from the phase 3 MajesTEC-3 trial (NCT05083169), which...